Schizophrenia Spectrum and Other Psychotic Disorders
44
8
10
24
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.5%
2 terminated out of 44 trials
92.3%
+5.8% vs benchmark
7%
3 trials in Phase 3/4
25%
6 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 24 completed trials
Clinical Trials (44)
A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
Early Psychosis Intervention - Spreading Evidence-based Treatment
Repetitive TMS & Cognitive Training in Adults With Schizophrenia
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
SloMo2: Implementation, Effectiveness, and Cost-effectiveness Study
Comparative Effectiveness of Dapagliflozin, Metformin, and Lifestyle Modification for Antipsychotic-Induced Weight Gain: An Open-Label Pragmatic Trial
Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic
State Representation in Early Psychosis - Project 4
Remote State Representation in Early Psychosis
State Representation in Early Psychosis
Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach
EPI-MINN: Targeting Cognition and Motivation - National
Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia
Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)
Sex, Psychopharmacology, and Diabetes
Plan D- Vitamin D Supplementation in Psychotic Disorders
The Personalized Psychological Treatment for Psychosis
VR-based Avatar Therapy for Treatment of Auditory Hallucinations
Music Therapy Advocacy Recording Intervention (MTAR) on Internalized Stigma